ABVC BioPharma, Inc. (ABVC) Dividend History

ABVC BioPharma, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for medical conditions such as neurological, psychiatric, and oncological disorders. The company leverages its expertise in biotechnology to advance drug discovery and development, with a particular emphasis on integrating traditional and modern medicine approaches. Headquartered in the United States, ABVC aims to address unmet medical needs through its pipeline of investigational therapies.

44370 Old Warm Springs Blvd., Fremont, CA, 94538
Phone: 510-668-0881
Website:

Dividend History

Pay Date Amount Ex Dividend Date Record Date
October 04, 2013 $0.29 09/16/2013 09/18/2013
April 04, 2013 $0.28 03/06/2013 03/08/2013
April 04, 2013 $0.04 03/06/2013 03/08/2013
January 29, 2013 $0.40 12/27/2012 12/31/2012
January 29, 2013 $0.05 12/27/2012 12/31/2012
Show more

Dividends Summary

  • ABVC BioPharma, Inc. has issued 57 dividend payments over the past 10 years
  • The most recent dividend was paid 4264 days ago, on October 4, 2013
  • The first recorded dividend was paid on October 17, 2003
  • The highest dividend payout was $1.65 per share
  • The average dividend over this 10 year span is $0.31 per share
  • ABVC BioPharma, Inc. has increased its dividend payments by 55.04% since 2003

Company News

  • FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.

    GlobeNewswire Inc.
  • FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the Company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.

    GlobeNewswire Inc.
  • FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including the financial statements included herein, can be found in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2024.

    GlobeNewswire Inc.
  • FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC’s botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.

    GlobeNewswire Inc.
  • Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance. For the fourth quarter, the company expects revenue of $634 million-$638 million (vs. $636.39 million) and adjusted operating income of $241 million-$247 million. The company's previous implied guidance was $623 million-$648 million in revenue. Wolfe Research analyst Shreyas Patil downgraded Mobileye Global from Outperform to Peer Perform. Mobileye Global shares dipped 23.5% to $30.37 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Minim, Inc. (NASDAQ: MINM) shares jumped 170.2% to $4.62. Omega Therapeutics, Inc. (NASDAQ: OMGA) gained 92.7% to $5.26 after Novo Nordisk entered into a research collaboration with the company. Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares climbed 65.8% to $0.2920 after the company announced it reached a final agreement with the FDA for the Phase 3 safety study for IV tramadol. Jeffs' Brands Ltd(NASDAQ: JFBR) gained 40% to $4.41 after surging 25% on Wednesday. Jeffs' Brands, last month, signed non-binding letters of intent with Sky Growth Partners to invest in a DLP laser-based system for counter-drone solutions and laser-based wireless charging technology. Mobix Labs, Inc. (NASDAQ: MOBX) gained 33.3% to $4.00. Mobix Labs was awarded 15-month contract to supply EMI filtered connectors as part of US Army's M-1 Abrams Tank Program. ATIF Holdings Limited (NASDAQ: ATIF) jumped 30.6% to $1.32. Adicet Bio, Inc. (NASDAQ: ACET) surged 26.1% to $2.22. Adicet Bio issued corporate updates and highlighted upcoming priorities for its pipeline programs in 2024. Smart for Life, Inc. (NASDAQ:

    Benzinga
Dividend data last updated 06/07/2025 07:26:06 UTC